🏳️⚧️
Gender-Affirming HRT Lab Guide
Understanding your lab results during hormone therapy — what to expect, what the numbers mean, and when to talk to your prescriber.
About Feminizing HRT
Feminizing hormone therapy typically uses estradiol to promote feminizing changes, and often an anti-androgen (such as spironolactone or bicalutamide) to suppress testosterone. Some people later add progesterone. Labs help confirm that estradiol is in a therapeutic range and testosterone is adequately suppressed.
🧪 Labs That Are Monitored
- Estradiol (E2)
- Testosterone, Total
- Testosterone, Free
- LH (Luteinizing Hormone)
- FSH (Follicle-Stimulating Hormone)
- Prolactin
- Potassium
- Sodium
- Creatinine / eGFR
- AST / ALT (liver enzymes)
- Complete Blood Count (CBC)
- Lipid Panel
- Blood Pressure
Not all providers order every lab every time. Your prescriber will determine what's most relevant to your regimen.
📅 When Labs Are Typically Drawn
Baseline — before starting HRT
3 months — after starting or any dose change
6 months — continued monitoring
Annually — once levels are stable
Timing your labs matters.
For injectable estradiol: your provider may ask you to test at "trough" (the day before your next injection) or "peak" (3–5 days after injection). Knowing which was used helps interpret results.
For patches or gel: test at mid-cycle (patches) or 2 hours after applying gel for a steady-state reading.
For oral/sublingual: timing varies — ask your prescriber.
🎯 Target Ranges
| Lab | Target / Goal Range | Why It Matters |
|---|---|---|
| Estradiol (E2) | 100–200 pg/mL (some providers: up to 300 pg/mL) |
Primary feminizing hormone; too low = reduced effect; too high = clot risk with oral |
| Testosterone, Total | <50 ng/dL (ideally <30 ng/dL) |
Suppression is key for feminization and reducing androgenic effects |
| Testosterone, Free | <5 pg/mL | Free T is the biologically active form — even if total T looks low, free T matters |
| Prolactin | <25 ng/mL (typical lab normal) | Elevated prolactin can indicate pituitary issues; monitor especially at higher E2 doses |
| Potassium | 3.5–5.0 mEq/L | Critical if on spironolactone, which raises potassium (hyperkalemia risk) |
| LH / FSH | Suppressed (both <2 mIU/mL is typical) | Suppression indicates the body is responding to exogenous estrogen |
| Hematocrit | 36–46% (may decrease slightly) | Estrogen can mildly lower hematocrit — this is expected and generally benign |
| AST / ALT | Within normal range | Liver enzymes; monitor with oral estrogen, though significant elevation is uncommon |
| HDL Cholesterol | >50 mg/dL | Estrogen typically improves the lipid profile (raises HDL, lowers LDL) |
👀 What to Pay Attention To
Most important marker: Testosterone suppression.
If testosterone is not suppressing below 50 ng/dL, anti-androgen adjustment is likely needed — this is usually the first thing a prescriber will address.
- Estradiol level context — always know whether you tested at peak or trough, and share that with your prescriber. A "low" reading at trough is expected; a "low" reading at steady state is not.
- Potassium (if on spironolactone) — a level above 5.1 mEq/L needs prompt attention. Avoid excessive potassium-rich foods and NSAIDs, which can worsen hyperkalemia.
- Prolactin elevation — a modest rise is common on estrogen, but significant elevation (>3× normal) warrants imaging to rule out pituitary adenoma.
- Mood and emotional pattern — mood instability, irritability, or anxiety can correlate with peaks and troughs. Tracking mood alongside your lab timing can be useful information for your prescriber.
- Blood pressure (if on spironolactone) — spiro lowers blood pressure; monitor for dizziness when standing (orthostatic hypotension).
- Cardiovascular risk — oral estrogen at high doses carries a small but real risk of blood clots (DVT/PE). Risk increases with smoking. Transdermal routes (patches, gel) carry lower clot risk.
⚕️ When to Consider Adding or Adjusting Hormones
- 1 Testosterone not suppressing (>50 ng/dL after 3+ months): Consider increasing anti-androgen dose, or switching from spironolactone to bicalutamide or a GnRH agonist. Discuss with prescriber.
- 2 Estradiol consistently below 100 pg/mL: May indicate dose needs to be increased, or route changed (e.g., oral → patch → injectable). Route affects absorption significantly.
- 3 Spironolactone not tolerated: Side effects like frequent urination, dizziness, or high potassium may prompt a switch to bicalutamide (no blood pressure or potassium effects) or a GnRH agonist.
- 4 Adding progesterone: Often considered after 1–2 years on HRT. Micronized progesterone (Prometrium) may support breast development, improve sleep, and improve mood for some. Evidence is still emerging. Discuss timing and form with your prescriber.
- 5 After orchiectomy (if applicable): Anti-androgen may no longer be needed. Many people transition to estrogen monotherapy. Labs should confirm testosterone remains suppressed.
- 6 Mood instability between doses: This may signal too-infrequent dosing. Splitting doses (e.g., daily instead of every other day) or switching routes can help smooth out levels.
📋 Sample Lab Results
These are illustrative examples only, not diagnostic standards. Individual variation is normal. Always interpret labs with your prescriber.
Before Starting HRT — Baseline
| Lab | Result | Lab Reference Range | Interpretation |
|---|---|---|---|
| Estradiol | 18 pg/mL | 10–40 pg/mL (male ref) | Expected |
| Testosterone, Total | 520 ng/dL | 280–800 ng/dL (male ref) | Expected baseline |
| LH | 4.2 mIU/mL | 1.7–8.6 mIU/mL | Normal |
| FSH | 3.1 mIU/mL | 1.5–12.4 mIU/mL | Normal |
| Prolactin | 8.4 ng/mL | 2–18 ng/mL | Normal |
| Potassium | 4.2 mEq/L | 3.5–5.1 mEq/L | Normal |
3 Months — Estradiol 2 mg oral + Spironolactone 100 mg
| Lab | Result | Target Range | Interpretation |
|---|---|---|---|
| Estradiol | 87 pg/mL | 100–200 pg/mL | Low — dose may need increase |
| Testosterone, Total | 68 ng/dL | <50 ng/dL | Above target — anti-androgen may need adjustment |
| LH | 1.1 mIU/mL | Suppressed | Suppressing well |
| FSH | 1.3 mIU/mL | Suppressed | Suppressing well |
| Prolactin | 14.2 ng/mL | <25 ng/mL | Normal, slight rise expected |
| Potassium | 4.8 mEq/L | 3.5–5.1 mEq/L | Upper normal — continue monitoring |
Prescriber may increase estradiol dose and/or increase spironolactone. Labs rechecked in 3 months.
6 Months — Estradiol 4 mg oral + Spironolactone 150 mg
| Lab | Result | Target Range | Interpretation |
|---|---|---|---|
| Estradiol | 142 pg/mL | 100–200 pg/mL | In target range |
| Testosterone, Total | 22 ng/dL | <50 ng/dL | Well suppressed |
| Prolactin | 16.8 ng/mL | <25 ng/mL | Normal — continue monitoring |
| Potassium | 5.0 mEq/L | 3.5–5.1 mEq/L | Upper normal — watch, avoid NSAIDs |
| HDL Cholesterol | 72 mg/dL | >50 mg/dL | Improved — estrogen benefit |
Labs at goal. Continue current regimen and recheck in 6 months, then annually.
About Masculinizing HRT
Masculinizing hormone therapy uses testosterone to promote virilizing changes. It comes in several forms: intramuscular or subcutaneous injectable (most common), daily gel, patch, or long-acting pellets. Labs confirm testosterone is in a therapeutic range and monitor key safety markers — especially hematocrit.
🧪 Labs That Are Monitored
- Testosterone, Total
- Testosterone, Free
- Estradiol (E2)
- Hematocrit
- Hemoglobin
- CBC with Differential
- LH / FSH
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
- Blood Pressure
📅 When Labs Are Typically Drawn
Baseline — before starting HRT
3 months — after starting or dose change
6 months — continued monitoring
Annually — once levels are stable
Timing your labs matters for injectables.
For testosterone cypionate/enanthate injections: many providers test at trough (the day of or before your next injection) to find your lowest point, or at peak (3–5 days after injection) to find your highest point. Ask your prescriber which they prefer — this context is essential for interpreting results.
For gel or patch: test at a consistent time, typically after a few weeks on a stable dose.
🎯 Target Ranges
| Lab | Target / Goal Range | Why It Matters |
|---|---|---|
| Testosterone, Total | 400–700 ng/dL (cisgender male ref: 300–1000 ng/dL) |
Primary masculinizing hormone; mid-range is generally the goal to balance effect and safety |
| Testosterone, Free | 5–21 ng/dL | The biologically active fraction; useful if total T looks normal but response seems low |
| Hematocrit | <50% (above 52% requires action) |
Most critical safety marker. Testosterone stimulates red blood cell production; elevated hematocrit thickens the blood and raises clot risk |
| Hemoglobin | <17 g/dL | Accompanies hematocrit monitoring; both rise together with testosterone |
| Estradiol (E2) | Often <50 pg/mL (naturally suppresses in most people) |
Testosterone aromatizes (converts) to estrogen; most people's levels suppress naturally; some variation is normal |
| LH / FSH | Suppressed | Confirms the body is responding to exogenous testosterone |
| HDL Cholesterol | >40 mg/dL | Testosterone tends to lower HDL ("good" cholesterol); worth monitoring over time for cardiovascular health |
👀 What to Pay Attention To
Most important safety marker: Hematocrit.
Elevated hematocrit (polycythemia) is the primary safety concern with testosterone therapy. It increases the risk of blood clots, stroke, and cardiovascular events. A hematocrit above 50% should be discussed with your prescriber promptly; above 52% typically requires a dose change or other intervention.
- Testosterone timing for injectables — mood dips, energy crashes, or emotional instability in the days before your next injection may indicate too-long dosing intervals. Tracking how you feel day-by-day relative to injection date can be helpful information for your prescriber.
- Menstrual cycles — most people experience cessation of periods within 3–6 months. Persistent bleeding at 6+ months (at a therapeutic T level) may warrant additional management (e.g., a progestin to suppress bleeding).
- Blood pressure — testosterone can raise blood pressure over time. Routine monitoring is important, especially with a personal or family history of hypertension.
- Lipid panel — testosterone tends to lower HDL cholesterol. Annual lipid monitoring helps track cardiovascular risk over time.
- Acne — common in the first 1–2 years; can be managed with standard dermatological approaches. Let your provider know if it's severe.
- Sleep apnea — testosterone can worsen or unmask sleep apnea. Report symptoms (snoring, excessive daytime sleepiness, waking unrefreshed) to your provider.
⚕️ When to Consider Adjusting or Adding Hormones
- 1 Testosterone below target range after 3+ months: Dose increase or shortening injection interval may be needed. Discuss with prescriber — absorption varies by injection site and individual.
- 2 Hematocrit above 50%: Do not ignore this. Options include reducing the dose, extending the interval, switching to a non-injectable route (gel/patch), or therapeutic phlebotomy (blood donation). Your prescriber will guide which is appropriate.
- 3 Mood instability or energy crashes between injections: Consider switching to weekly (rather than biweekly) injections, or transitioning to daily gel or patch for smoother levels.
- 4 Persistent menstrual bleeding after 6 months at target T levels: A progestin (such as norethindrone or medroxyprogesterone acetate) can be added to suppress bleeding. This is common and manageable.
- 5 Virilization stalled despite testosterone in range: Consider checking free testosterone and discussing with your prescriber. Some changes (e.g., voice, bottom growth) are largely genetic and may not accelerate further with dosage changes.
- 6 Significant HDL decline or cardiovascular risk factors: Lifestyle changes (exercise, diet) and closer monitoring are the first steps. Rarely, a dosage reduction or medication adjustment may be considered.
📋 Sample Lab Results
These are illustrative examples only, not diagnostic standards. Individual variation is normal. Always interpret labs with your prescriber.
Before Starting HRT — Baseline
| Lab | Result | Lab Reference Range | Interpretation |
|---|---|---|---|
| Testosterone, Total | 28 ng/dL | 15–70 ng/dL (female ref) | Expected baseline |
| Estradiol | 112 pg/mL | Variable (female ref) | Expected baseline |
| Hematocrit | 38% | 36–46% (female ref) | Normal |
| Hemoglobin | 12.8 g/dL | 12–16 g/dL (female ref) | Normal |
| LH | 6.8 mIU/mL | 1.7–8.6 mIU/mL | Normal |
| HDL Cholesterol | 68 mg/dL | >50 mg/dL | Normal |
3 Months — Testosterone Cypionate 40 mg/week (subcutaneous)
| Lab | Result | Target Range | Interpretation |
|---|---|---|---|
| Testosterone, Total | 380 ng/dL | 400–700 ng/dL | Just below target — approaching goal |
| Estradiol | 42 pg/mL | <50 pg/mL | Suppressing well |
| Hematocrit | 41% | <50% | Rising — safe range |
| Hemoglobin | 13.6 g/dL | <17 g/dL | Normal, trending up |
| LH | 0.4 mIU/mL | Suppressed | Suppressed as expected |
Prescriber may slightly increase dose to 50 mg/week. Recheck in 3 months.
6 Months — Testosterone Cypionate 50 mg/week
| Lab | Result | Target Range | Interpretation |
|---|---|---|---|
| Testosterone, Total | 562 ng/dL | 400–700 ng/dL | In target range |
| Estradiol | 31 pg/mL | <50 pg/mL | Well suppressed |
| Hematocrit | 46% | <50% | Elevated — monitor closely |
| Hemoglobin | 15.2 g/dL | <17 g/dL | Elevated — watch trend |
| HDL Cholesterol | 48 mg/dL | >40 mg/dL | Mild decline from baseline — monitor |
Labs in good range. Hematocrit near the upper end — prescriber may discuss hydration, blood donation, and monitoring frequency. Recheck in 6 months.
A note about 1-year labs vs. 6-month labs
For masculinizing HRT, 1-year labs do not always look like 6-month labs. Hematocrit and hemoglobin can continue rising through year 1 and into year 2, even on a stable dose — someone at 46% at 6 months could be at 49–51% at 12 months. This is one of the main reasons annual labs remain important even when things feel stable. HDL decline can also continue gradually over time. For feminizing HRT, 1-year labs are more likely to be stable if the dose hasn't changed, though prolactin may continue a slow, gradual rise with ongoing estrogen exposure.
Important Note
This resource is for educational purposes only. It is intended to help you understand and navigate your lab results — not to replace the guidance of your prescribing provider. Lab reference ranges vary between laboratories, and target ranges for gender-affirming HRT are guidelines, not rigid rules. Always discuss your results with your prescriber before making any changes to your medication. If you have concerns about a lab result, contact your medical provider directly.
Created by Cooper Counseling PLLC | coopercounselingpllc.com
This resource is for educational purposes only. It is intended to help you understand and navigate your lab results — not to replace the guidance of your prescribing provider. Lab reference ranges vary between laboratories, and target ranges for gender-affirming HRT are guidelines, not rigid rules. Always discuss your results with your prescriber before making any changes to your medication. If you have concerns about a lab result, contact your medical provider directly.
Created by Cooper Counseling PLLC | coopercounselingpllc.com